MedTrace Logo

VA CoronavirUs Research and Efficacy Studies-1

NCT04539275 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2022-09-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if treatment with convalescent plasma improves the clinical outcomes of Veterans who are hospitalized and require supplemental oxygen due to COVID-19.

Conditions

Interventions

DRUG

Convalescent Plasma

Convalescent plasma from persons recovered from SARS-CoV-2 is being used to treat hospitalized individuals with complicated COVID-19 infection.

OTHER

Masked Saline Placebo

0.9% saline solution will be used as the Masked Saline Placebo

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Edward N. Janoff, MD · Rocky Mountain Regional VA Medical Center, Aurora, CO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-16
Primary Completion
2021-06-30
Completion
2021-09-30
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04539275 on ClinicalTrials.gov